Stock ACLS THER
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases ACLS THER Nasdaq

Equities

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for ACLS THER
07-16 Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly MT
07-05 Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
AQ
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
AQ
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Aclaris Therapeutics : ITK Portfolio
PU
Aclaris: Q1 Earnings Snapshot
AQ
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
AQ
FLARE THERAPEUTICS APPOINTS DOUGLAS MANION, M.D., FRCP AS CHIEF EXECUTIVE OFFICER
AQ
Aclaris: Q4 Earnings Snapshot
AQ
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
AQ
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
AQ
Aclaris Therapeutics Provides Corporate Update
AQ
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
AQ
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
AQ
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Aclaris: Q3 Earnings Snapshot
AQ
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis
AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACRS Stock
  4. Stock
  5. News ACLS THER
  6. Press Releases